Boston Biomedical reports detailed data from Phase III gastric cancer trial of napabucasin

The Boston Biomedical Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) reported data from the Phase III BRIGHTER trial in 714 patients

Read the full 237 word article

User Sign In